Progress in Pediatric Cardiology
Volume 26, Issue 1 , Pages 31-37 , January 2009

Current practice in immunosuppression in pediatric cardiac transplantation

  • Rebecca K. Ameduri

      Affiliations

    • Division of Pediatric Cardiology, Department of Pediatrics, University of Minnesota, Minneapolis, MN, USA
    • ,
  • Charles E. Canter

      Affiliations

    • Division of Pediatric Cardiology, Department of Pediatrics, Washington University, 1 Children's Place, St. Louis, MO 63110, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1 314 454 6095; fax: +1 314 454 2561.

References 

  1. Boucek MM, Aurora P, Edwards LB, et al. Registry of the International Society for Heart and Lung Transplantation: tenth official pediatric heart transplantation report--2007. J Heart Lung Transplant. 2007;26:796–807
  2. Reding R, Webber SA, Fine R. Getting rid of steroids in pediatric solid-organ transplantation?. Pediatr Transplant. 2004;8:526–530
  3. Leonard H, Hornung T, Parry G, Dark JH. Pediatric cardiac transplant: results using a steroid-free maintenance regimen. Pediatr Transplant. 2003;7:59–63
  4. Oberholzer J, John E, Lumpaopong A, et al. Early discontinuation of steroids is safe and effective in pediatric kidney transplant recipients. Pediatr Transplant. 2005;9:456–463
  5. Boucek RJ, Naftel D, Boucek MM, et al. Induction immunotherapy in pediatric heart transplant recipients: a multicenter study. J Heart Lung Transplant. 1999;18:460–469
  6. Di Filippo S, Boissonnat P, Sassolas F, et al. Rabbit antithymocyte globulin as induction immunotherapy in pediatric heart transplantation. Transplantation. 2003;75:354–358
  7. Parisi F, Danesi H, Squitieri C, Di Chiara L, Rava L, Di Donato RM. Thymoglobuline use in pediatric heart transplantation. J Heart Lung Transplant. 2003;22:591–593
  8. Chin C, Pittson S, Luikart H, Bernstein D, et al. Induction therapy for pediatric and adult heart transplantation: comparison between OKT3 and daclizumab. Transplantation. 2005;80:477–481
  9. Di Filippo S. Anti-IL-2 receptor antibody vs. polyclonal anti-lymphocyte antibody as induction therapy in pediatric transplantation. Pediatr Transplant. 2005;9:373–380
  10. Smith JM, Nemeth TL, McDonald RA. Current immunosuppressive agents: efficacy, side effects, and utilization. Pediatr Clin North Am. 2003;50:1283–1300
  11. Lindenfeld J, Miller GG, Shakar SF, et al. Drug therapy in the heart transplant recipient: part I: cardiac rejection and immunosuppressive drugs. Circulation. 2004;110:3734–3740
  12. Clark G, Walsh G, Deshpande P, Koffman G. Improved efficacy of basiliximab over antilymphocyte globulin induction therapy in paediatric renal transplantation. Nephrol Dial Transplant. 2002;17:1304–1309
  13. Sweet SC, De La Morena MT, Shapiro SD, Mendeloff EN, Huddleston CB. Interleukin-2-receptor blockade with daclizumab decreases the incidence of acute rejection in pediatric lung transplant recipients. J Heart Lung Transplant. 2001;20:221–222
  14. Ford KA, Cale CM, Rees PG, Elliott MJ, Burch M. Initial data on basiliximab in critically ill children undergoing heart transplantation. J Heart Lung Transplant. 2005;24:1284–1288
  15. Al-khaldi A, Robbins RC. New directions in cardiac transplantation. Annu Rev Med. 2006;57:455–471
  16. Canter CE, Moorhead S, Saffitz JE, Huddleston CB, Spray TL. Steroid withdrawal in the pediatric heart transplant recipient initially treated with triple immunosuppression. J Heart Lung Transplant. 1994;13:74–79discussion 79-80
  17. Esmore DS, Spratt PM, Keogh AM, Chang VP. Cyclosporine and azathioprine immunosuppression without maintenance steroids: a prospective randomized trial. J Heart Transplant. 1989;8:194–199
  18. Lee KF, Pierce JD, Hess ML, Hastillo AK, Wechsler AS, Guerraty AJ. Cardiac transplantation with corticosteroid-free immunosuppression: long-term results. Ann Thorac Surg. 1991;52:211–217discussion 218
  19. Renlund DG, O'Connell JB, Gilbert EM, Watson FS, Bristow MR. Feasibility of discontinuation of corticosteroid maintenance therapy in heart transplantation. J Heart Transplant. 1987;6:71–78
  20. Barone G, Chang CT, Choc MG, et al. The pharmacokinetics of a microemulsion formulation of cyclosporine in primary renal allograft recipients. The Neoral Study Group. Transplantation. 1996;61:875–880
  21. Holmberg C, Laine J, Jalanko H, Leijala M, Hoppu K. Conversion from cyclosporine to Neoral in pediatric recipients for kidney, liver, and heart transplantation. Transplant Proc. 1996;28:2262–2263
  22. Lindenfeld J, Miller GG, Shakar SF, et al. Drug therapy in the heart transplant recipient: part II: immunosuppressive drugs. Circulation. 2004;110:3858–3865
  23. Pietra BA, Boucek MM. Immunosuppression for pediatric cardiac transplantation in the modern era. Prog Pediatr Cardiol. 2000;11:115–129
  24. Kobashigawa JA, Patel J, Furukawa H, et al. Five-year results of a randomized, single-center study of tacrolimus vs microemulsion cyclosporine in heart transplant patients. J Heart Lung Transplant. 2006;25:434–439
  25. Pollock-Barziv SM, Dipchand AI, McCrindle BW, Nalli N, West LJ. Randomized clinical trial of tacrolimus- vs cyclosporine-based immunosuppression in pediatric heart transplantation: preliminary results at 15-month follow-up. J Heart Lung Transplant. 2005;24:190–194
  26. Armitage JM, Fricker FJ, del Nido P, Starzl TE, Hardesty RL, Griffith BP. A decade (1982 to 1992) of pediatric cardiac transplantation and the impact of FK 506 immunosuppression. J Thorac Cardiovasc Surg. 1993;105:464–472discussion 472-463
  27. Filler G, Webb NJ, Milford DV, et al. Four-year data after pediatric renal transplantation: a randomized trial of tacrolimus vs. cyclosporin microemulsion. Pediatr Transplant. 2005;9:498–503
  28. Leman NR, Levi DS, Alejos JC, Wetzel GT. Predictors of graft longevity in pediatric heart transplantation. Pediatr Cardiol. 2005;26:762–767
  29. English RF, Pophal SA, Bacanu SA, et al. Long-term comparison of tacrolimus- and cyclosporine-induced nephrotoxicity in pediatric heart-transplant recipients. Am J Transplant. 2002;2:769–773
  30. Cantin B, Kwok BW, Shiba N, Valantine HA, Hunt SA, Chan MC. Post-operative conversion from cyclosporine to tacrolimus in heart transplantation: a single-center experience. J Heart Lung Transplant. 2003;22:723–730
  31. Treede H, Klepetko W, Reichenspurner H, et al. Tacrolimus versus cyclosporine after lung transplantation: a prospective, open, randomized two-center trial comparing two different immunosuppressive protocols. J Heart Lung Transplant. 2001;20:511–517
  32. Kobashigawa JA, Meiser BM. Review of major clinical trials with mycophenolate mofetil in cardiac transplantation. Transplantation. 2005;80:S235–S243
  33. Kobashigawa JA, Tobis JM, Mentzer RM, et al. Mycophenolate mofetil reduces intimal thickness by intravascular ultrasound after heart transplant: reanalysis of the multicenter trial. Am J Transplant. 2006;6:993–997
  34. Boucek MM, Waltz DA, Edwards LB, et al. Registry of the International Society for Heart and Lung Transplantation: ninth official pediatric heart transplantation report--2006. J Heart Lung Transplant. 2006;25:893–903
  35. Frazier E, Naftel DC, Canter CE, et al. Death after cardiac transplantation in children: who dies, when, and why [abstract]. J Heart Lung Transplant. 1999;18:69–70
  36. Mulla NF, Johnston JK, Vander Dussen L, et al. Late rejection is a predictor of transplant coronary artery disease in children. J Am Coll Cardiol. 2001;37:243–250
  37. Nicolas RT, Kort HW, Balzer DT, et al. Surveillance for transplant coronary artery disease in infant, child and adolescent heart transplant recipients: an intravascular ultrasound study. J Heart Lung Transplant. 2006;25:921–927
  38. Billingham ME, Cary NR, Hammond ME, et al. A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection: Heart Rejection Study Group. The International Society for Heart Transplantation. J Heart Transplant. 1990;9:587–593
  39. Boucek MM, Mathis CM, Kanakriyeh MS, Hodgkin DD, Boucek RJ, Bailey LL. Serial echocardiographic evaluation of cardiac graft rejection after infant heart transplantation. J Heart Lung Transplant. 1993;12:824–831
  40. Boucek MM, Mathis CM, Boucek RJ, et al. Prospective evaluation of echocardiography for primary rejection surveillance after infant heart transplantation: comparison with endomyocardial biopsy. J Heart Lung Transplant. 1994;13:66–73
  41. Fullerton DA, Campbell DN, Jones SD, et al. Heart transplantation in children and young adults: early and intermediate-term results. Ann Thorac Surg. 1995;59:804–811discussion 811-802
  42. Tantengco MV, Dodd D, Frist WH, Boucek MM, Boucek RJ. Echocardiographic abnormalities with acute cardiac allograft rejection in children: correlation with endomyocardial biopsy. J Heart Lung Transplant. 1993;12:S203–210
  43. Canter CE, Appleton RS, Saffitz JE, et al. Surveillance for rejection by echocardiographically guided endomyocardial biopsy in the infant heart transplant recipient. Circulation. 1991;84:III310–III315
  44. Chin C, Akhtar MJ, Rosenthal DN, Bernstein D. Safety and utility of the routine surveillance biopsy in pediatric patients 2 years after heart transplantation. J Pediatr. 2000;136:238–242
  45. Chin C, Naftel DC, Singh TP, et al. Risk factors for recurrent rejection in pediatric heart transplantation: a multicenter experience. J Heart Lung Transplant. 2004;23:178–185
  46. Zales VR, Crawford S, Backer CL, et al. Role of endomyocardial biopsy in rejection surveillance after heart transplantation in neonates and children. J Am Coll Cardiol. 1994;23:766–771
  47. Kuhn MA, Deming DD, Cephus CE, et al. Moderate acute rejection detected during annual catheterization in pediatric heart transplant recipients. J Heart Lung Transplant. 2003;22:276–280
  48. Frigerio M, Bonacina E, Gronda E, et al. A semiquantitative approach to the evaluation of acute cardiac allograft rejection at endomyocardial biopsy. J Heart Lung Transplant. 1997;16:1087–1098
  49. Kobashigawa JA, Patel JK. Immunosuppression for heart transplantation: where are we now?. Nat Clin Pract Cardiovasc Med. 2006;3:203–212
  50. Rizeq MN, Masek MA, Billingham ME. Acute rejection: significance of elapsed time after transplantation. J Heart Lung Transplant. 1994;13:862–868
  51. Delgado DH, Luu L, Edwards J, Cardella C, Rao V, Ross HJ. Should moderate acute rejection of a cardiac transplant graft be treated?. Clin Transplant. 2002;16:217–221
  52. Park MH, Starling RC, Ratliff NB, et al. Oral steroid pulse without taper for the treatment of asymptomatic moderate cardiac allograft rejection. J Heart Lung Transplant. 1999;18:1224–1227
  53. Di Filippo S, Girnita A, Webber SA, et al. Impact of ELISA-detected anti-HLA antibodies on pediatric cardiac allograft outcome. Hum Immunol. 2005;66:513–518
  54. Cantarovich M, Latter DA, Loertscher R. Treatment of steroid-resistant and recurrent acute cardiac transplant rejection with a short course of antibody therapy. Clin Transplant. 1997;11:316–321
  55. Ferraro P, Carrier M, White M, Pelletier GB, Pelletier LC. Antithymocyte globulin and methotrexate therapy of severe or persistent cardiac allograft rejection. Ann Thorac Surg. 1995;60:372–376
  56. De Bonis M, Reynolds L, Barros J, Madden BP. Tacrolimus as a rescue immunosuppressant after heart transplantation. Eur J Cardiothorac Surg. 2001;19:690–695
  57. Kobashigawa JA, Miller LW, Russell SD, Ewald GA, Zucker MJ, Goldberg LR, et al. Tacrolimus with mycophenolate mofetil (MMF) or sirolimus vs. cyclosporine with MMF in cardiac transplant patients: 1-year report. Am J Transplant. 2006;6:1377–1386
  58. Mathieu P, Carrier M, White M, et al. Conversion of cyclosporine A to tacrolimus following heart transplantation. Can J Cardiol. 1999;15:1229–1232
  59. Yamani MH, Starling RC, Pelegrin D, et al. Efficacy of tacrolimus in patients with steroid-resistant cardiac allograft cellular rejection. J Heart Lung Transplant. 2000;19:337–342
  60. Boucek MM, Pietra B, Sondheimer H, et al. Anti-T-cell-antibody prophylaxis in children: success with a novel combination strategy of mycophenolate mofetil and antithymocyte serum. Transplant Proc. 1997;29:16S–20S
  61. Kirklin JK, George JF, McGiffin DC, Naftel DC, Salter MM, Bourge RC. Total lymphoid irradiation: is there a role in pediatric heart transplantation?. J Heart Lung Transplant. 1993;12:S293–S300
  62. Wolden SL, Tate DJ, Hunt SA, Strober S, Hoppe RT. Long-term results of total lymphoid irradiation in the treatment of cardiac allograft rejection. Int J Radiat Oncol Biol Phys. 1997;39:953–960
  63. Asano M, Gundry SR, Razzouk AJ, et al. Total lymphoid irradiation for refractory rejection in pediatric heart transplantation. Ann Thorac Surg. 2002;74:1979–1985
  64. Chin C, Hunt S, Robbins R, Hoppe R, Reitz B, Bernstein D. Long-term follow-up after total lymphoid irradiation in pediatric heart transplant recipients. J Heart Lung Transplant. 2002;21:667–673
  65. Dall'Amico R, Montini G, Murer L, et al. Benefits of photopheresis in the treatment of heart transplant patients with multiple/refractory rejection. Transplant Proc. 1997;29:609–611
  66. Lehrer MS, Rook AH, Tomaszewski JE, DeNofrio D. Successful reversal of severe refractory cardiac allograft rejection by photopheresis. J Heart Lung Transplant. 2001;20:1233–1236
  67. Michaels PJ, Espejo ML, Kobashigawa J, et al. Humoral rejection in cardiac transplantation: risk factors, hemodynamic consequences and relationship to transplant coronary artery disease. J Heart Lung Transplant. 2003;22:58–69
  68. Shaddy RE, Fuller TC. The sensitized pediatric heart transplant candidate: causes, consequences, and treatment options. Pediatr Transplant. 2005;9:208–214
  69. Xydas S, Yang JK, Burke EM, et al. Utility of post-transplant anti-HLA antibody measurements in pediatric cardiac transplant recipients. J Heart Lung Transplant. 2005;24:1289–1296
  70. Berglin E, Kjellstrom C, Mantovani V, Stelin G, Svalander C, Wiklund L. Plasmapheresis as a rescue therapy to resolve cardiac rejection with vasculitis and severe heart failure. A report of five cases. Transpl Int. 1995;8:382–387
  71. Grauhan O, Knosalla C, Ewert R, et al. Plasmapheresis and cyclophosphamide in the treatment of humoral rejection after heart transplantation. J Heart Lung Transplant. 2001;20:316–321
  72. Jordan SC, Quartel AW, Czer LS, et al. Posttransplant therapy using high-dose human immunoglobulin (intravenous gammaglobulin) to control acute humoral rejection in renal and cardiac allograft recipients and potential mechanism of action. Transplantation. 1998;66:800–805
  73. Zhu LP, Cupps TR, Whalen G, Fauci AS. Selective effects of cyclophosphamide therapy on activation, proliferation, and differentiation of human B cells. J Clin Invest. 1987;79:1082–1090
  74. Rose ML, Smith J, Dureau G, Keogh A, Kobashigowa J. Mycophenolate mofetil decreases antibody production after cardiac transplantation. J Heart Lung Transplant. 2002;21:282–285
  75. Aranda JM, Scornik JC, Normann SJ, et al. Anti-CD20 monoclonal antibody (rituximab) therapy for acute cardiac humoral rejection: a case report. Transplantation. 2002;73:907–910
  76. Baran DA, Lubitz S, Alvi S, et al. Refractory humoral cardiac allograft rejection successfully treated with a single dose of rituximab. Transplant Proc. 2004;36:3164–3166
  77. Garrett HE, Duvall-Seaman D, Helsley B, Groshart K. Treatment of vascular rejection with rituximab in cardiac transplantation. J Heart Lung Transplant. 2005;24:1337–1342
  78. Webber SA, Naftel DC, Parker J, et al. Late rejection episodes more than 1 year after pediatric heart transplantation: risk factors and outcomes. J Heart Lung Transplant. 2003;22:869–875
  79. Mills RM, Naftel DC, Kirklin JK, et al. Heart transplant rejection with hemodynamic compromise: a multiinstitutional study of the role of endomyocardial cellular infiltrate. Cardiac Transplant Research Database. J Heart Lung Transplant. 1997;16:813–821
  80. Pahl E, Naftel DC, Canter CE, Frazier EA, Kirklin JK, Morrow WR. Death after rejection with severe hemodynamic compromise in pediatric heart transplant recipients: a multi-institutional study. J Heart Lung Transplant. 2001;20:279–287
  81. McOmber D, Ibrahim J, Lublin DM, et al. Non-ischemic left ventricular dysfunction after pediatric cardiac transplantation: treatment with plasmapheresis and OKT3. J Heart Lung Transplant. 2004;23:552–557
  82. Pahl E, Crawford SE, Cohn RA, et al. Reversal of severe late left ventricular failure after pediatric heart transplantation and possible role of plasmapheresis. Am J Cardiol. 2000;85:735–739
  83. Gregory CR. Immunosuppressive approaches to the prevention of graft vascular disease. Transplant Proc. 1998;30:878–880
  84. Kuppahally S, Al-Khaldi A, Weisshaar D, et al. Wound healing complications with de novo sirolimus versus mycophenolate mofetil-based regimen in cardiac transplant recipients. Am J Transplant. 2006;6:986–992
  85. Balfour IC, Srun SW, Wood EG, Belsha CW, Marshall DL, Ferdman BR. Early renal benefit of rapamycin combined with reduced calcineurin inhibitor dose in pediatric heart transplantation patients. J Heart Lung Transplant. 2006;25:518–522
  86. Lobach NE, Pollock-Barziv SM, West LJ, Dipchand AI. Sirolimus immunosuppression in pediatric heart transplant recipients: a single-center experience. J Heart Lung Transplant. 2005;24:184–189
  87. Keogh A, Richardson M, Ruygrok P, et al. Sirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary artery disease at 2 years: a randomized clinical trial. Circulation. 2004;110:2694–2700
  88. Das BB, Shoemaker L, Subramanian S, Johnsurde C, Recto M, Austin EH. Acute Sirolimus Pulmonary Toxicity in an Infant Heart Transplant Recipient: Case Report and Literature Review. J Heart Lung Transplant. 2007;26:296–298
  89. Eisen HJ, Tuzcu EM, Dorent R, et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac transplant recipients. N Engl J Med. 2003;349:847–858
  90. Chin C, Gamberg P, Miller J, Luikart H, Benstein D. Efficacy and Safety of Atorvastatin After Pediatric Heart Transplantation. J Heart Lung Transplant. 2002;21:1213–1217
  91. Chin C, Bernstein D. Pharmocotherapy of Hyperlipidemia in Pediatric Heart Transplant Recipients. Pediatr Drugs. 2005;7:391–396
  92. Kavey RE, Allada V, Daniels SR, et al. Cardiovascular Risk Reduction in High-Risk Pediatric Patients: a scientific statement from the American Heart Association Expert Panel on Population and Prevention Science; the Concils on Cardiovascular Disease in the Young, Epidemiology and Prevention, Nutrition, Phhysical Activity and Metabolism, High Blood Pressure Research, Cardiovascular Nursing, and the Kidney in Heart Disease; and the Interdisciplinary Working Group on Quality of Care and Outcomes Research; endorsed by the American Academy of Pediatrics. Circulation. 2006;114:2710–2738
  93. Mahle WT, Vincent RN, Berg AM, Kanter KR. Pravastatin Therapy is Associated with Reduction in Coronary Allograft Vasculopathy in Pediatric Heart Transplantation. J Heart Lung Transplant. 2005;24:63–66

PII: S1058-9813(08)00066-0

doi: 10.1016/j.ppedcard.2008.10.004

Progress in Pediatric Cardiology
Volume 26, Issue 1 , Pages 31-37 , January 2009

Article Tools